In this study, a quarter of patients with type 2 diabetes mellitus who initiated basal insulin (BI) therapy due to uncontrolled hyperglycaemia by OADs discontinued BI therapy within 6‐month follow‐up. This evidence concerns the gene INS and type 2 diabetes mellitus.